JP2023538963A5 - - Google Patents
Info
- Publication number
- JP2023538963A5 JP2023538963A5 JP2023513939A JP2023513939A JP2023538963A5 JP 2023538963 A5 JP2023538963 A5 JP 2023538963A5 JP 2023513939 A JP2023513939 A JP 2023513939A JP 2023513939 A JP2023513939 A JP 2023513939A JP 2023538963 A5 JP2023538963 A5 JP 2023538963A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- responsive
- subjects
- classifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073336P | 2020-09-01 | 2020-09-01 | |
| US63/073,336 | 2020-09-01 | ||
| PCT/US2021/048346 WO2022051245A2 (en) | 2020-09-01 | 2021-08-31 | Methods and systems for predicting response to anti-tnf therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538963A JP2023538963A (ja) | 2023-09-12 |
| JP2023538963A5 true JP2023538963A5 (https=) | 2024-08-26 |
Family
ID=80492102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513939A Pending JP2023538963A (ja) | 2020-09-01 | 2021-08-31 | 抗ｔｎｆ治療に対する応答を予測するための方法およびシステム |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230282367A1 (https=) |
| EP (1) | EP4208256A4 (https=) |
| JP (1) | JP2023538963A (https=) |
| KR (1) | KR20240018404A (https=) |
| CN (1) | CN117615780A (https=) |
| AU (1) | AU2021336781A1 (https=) |
| CA (1) | CA3191195A1 (https=) |
| GB (1) | GB2616129A (https=) |
| IL (1) | IL300978A (https=) |
| MX (1) | MX2023002446A (https=) |
| WO (1) | WO2022051245A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7496324B2 (ja) | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| GB2603294A (en) | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
| WO2023150731A2 (en) * | 2022-02-04 | 2023-08-10 | Scipher Medicine Corporation | Systems and methods for predicting response to anti-tnf therapies |
| CN120015309B (zh) * | 2025-01-14 | 2025-12-12 | 中国人民解放军军事科学院军事医学研究院 | 用于急性高原反应（ams）易感性分群的装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008150491A2 (en) * | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| US20100303813A1 (en) * | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| ES2445892T3 (es) * | 2008-08-25 | 2014-03-05 | Janssen Biotech, Inc. | Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados |
| WO2015148809A1 (en) * | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| US12105089B2 (en) * | 2017-07-17 | 2024-10-01 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
| JP7496324B2 (ja) * | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| EA202191354A1 (ru) * | 2018-11-15 | 2021-08-11 | Янссен Байотек, Инк. | Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника |
| GB2603294A (en) * | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
-
2021
- 2021-08-31 KR KR1020237011014A patent/KR20240018404A/ko active Pending
- 2021-08-31 CA CA3191195A patent/CA3191195A1/en active Pending
- 2021-08-31 MX MX2023002446A patent/MX2023002446A/es unknown
- 2021-08-31 WO PCT/US2021/048346 patent/WO2022051245A2/en not_active Ceased
- 2021-08-31 CN CN202180074291.7A patent/CN117615780A/zh active Pending
- 2021-08-31 AU AU2021336781A patent/AU2021336781A1/en not_active Abandoned
- 2021-08-31 GB GB2303624.7A patent/GB2616129A/en active Pending
- 2021-08-31 IL IL300978A patent/IL300978A/en unknown
- 2021-08-31 EP EP21864967.1A patent/EP4208256A4/en not_active Withdrawn
- 2021-08-31 JP JP2023513939A patent/JP2023538963A/ja active Pending
-
2023
- 2023-02-28 US US18/176,288 patent/US20230282367A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538963A5 (https=) | ||
| JP7297015B2 (ja) | エピジェネティックな染色体相互作用 | |
| JP2021518432A5 (https=) | ||
| GB2603294A (en) | Developing classifiers for stratifying patients | |
| JP2022541125A5 (https=) | ||
| GB2616129A (en) | Methods and systems for predicting response to anti-TNF therapies | |
| US20160002732A1 (en) | Molecular diagnostic test for cancer | |
| CN110168106B (zh) | 预测进展期胃癌患者的术后预后或抗癌药物适合性的系统 | |
| CA2852954A1 (en) | Methods for improving inflammatory bowel disease diagnosis | |
| CN107058521B (zh) | 一种检测人体免疫状态的检测系统 | |
| CN107523626B (zh) | 一组用于活动性肺结核无创诊断的外周血基因标记物 | |
| WO2016050111A1 (en) | Biomarkers for rheumatoid arthritis and usage thereof | |
| CA3078278A1 (en) | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression | |
| CN113755596B (zh) | 一种检测喉鳞癌放疗敏感性相关基因atm和atr基因突变的试剂盒及其应用 | |
| GB2622147A (en) | Methods of classifying and treating patients | |
| JP2024521748A (ja) | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 | |
| JP2023536636A5 (https=) | ||
| WO2012149107A2 (en) | Stratifying patient populations through characterization of disease-driving signaling | |
| CN112481380A (zh) | 一种评估晚期膀胱癌抗肿瘤免疫治疗反应性和预后生存的标志物及其应用 | |
| HK40100171A (en) | Methods and systems for predicting response to anti-tnf therapies | |
| CN110511995A (zh) | 一组结核病标志物及其应用 | |
| Pu et al. | Focusing on non-responders to infliximab with ulcerative colitis, what can we do first and next? | |
| WO2019087200A1 (en) | Prognostic methods for anti-tnfa treatment | |
| WO2016090255A1 (en) | Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same | |
| Blundell et al. | Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? |